ew remission care pathway: Diabetes Adaptive Weight management Network

niversity of Oxford0 个研究点目标入组 1,788 人开始时间: 2023年8月7日最近更新: 2023年10月23日

适应症

试验速览

暂无简介。

•1. Participant is willing and able to give informed consent for participation in the study
•2. Adults (aged 18 to 70 years) with type 2 diabetes diagnosed in the past 1 year
•3. A BMI of at least 27 kg/m² and who may benefit from achieving remission
•4. Able to attend baseline visits, adhere to intervention and follow-up appointments
•5. Participant is registered at a GP practice that is open for recruitment
•6. Participant is willing to be randomised to either treatment option

•1. Currently diagnosed with type 2 diabetes but who are in remission
•2. People currently following the Pathway to Remission programme, or who have previously followed this programme
•3. Currently using insulin injections
•4. GLP1-agonists or SGLT2 inhibitors started in the 3 months prior to study enrolment
•5. Currently taking an SGLT2 inhibitor for an indication other than type 2 diabetes
•6. Diagnosed with a known eating disorder for whom the programme could be unsafe or require extensive monitoring to ensure safety
•7. People who are pregnant or planning pregnancy
•8. People who are breastfeeding
•9. Diagnosed with a recent myocardial infarction or stroke in the past three months, uncontrolled cardiac conduction abnormalities e.g. long QT syndrome, maculopathy or proliferative retinopathy
•10. People with HbA1c =87mmol/mol
•11. People with significant life-limiting illnesses that mean that remission is unlikely to improve health
•(severe cardiac failure, palliatively treated cancer, dementia), other current severe illness or planned major surgery that means that following a weight loss programme would not be possible
•12. People taking part in other research that would compromise either their participation in NewDAWN or the other research study/ies that they are participating in

发起方